EUCTR2018-000226-58-BG进行中（未招募）1 期
A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of and is capable of comprehending all pertinent aspects of the study
- •2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •3. Subject is at least 18 years old (or the minimum country-specific age
- •of consent if > 18) at the screening visit
- •4. The subject has a diagnosis of AS based on the Modified New York Criteria for Ankylosing Spondylitis (1984).
- •5. The subject must have a radiograph of the SI joints (AP Pelvis) documenting diagnosis of AS. Previous radiographs (up to 2 years old) can be used if they are accepted by the central reader. Otherwise, a new radiograph will be obtained during the screening period.
- •6. Subject has active AS Screening and Baseline (Day 1) visits defined as:
- •BASDAI score of =4; and
- •Back pain score (BASDAI Question 2) of =4.
- •7. Subject has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or is intolerant to NSAIDsas defined in the
- •protocol. Subjects who are designated as TNFi-IR must have received at least 1, but not more than 2 approved TNF inhibiting biologic agent that was administered in accordance with its labeling recommendations and was inadequately effective after the minimum treatment times listed below and/or not tolerated after one or more doses.
- •At least 3 months of adalimumab treatment;
- •At least 3 months of etanercept treatment;
- •At least 4 infusions of infliximab;
- •At least 3 injections of golimumab;
- •At least 3 months of certolizumab treatment.
- •Intolerance is defined as having experienced a treatment-related AE (eg, infusion/injection reactions, infections, laboratory test changes, etc)
- •8. Subjects may be receiving the following csDMARDs at the time of the screening visit. These medications should be continued throughout the entire study and doses should remain unchanged. Any other DMARDs require discussion prior to enrollment with the sponsor for washout timeframe.
- •Methotrexate (MTX): Maximum dose of 25 mg/week. Minimum duration of therapy 4 months and dose stable for 4 weeks prior to first dose of investigational product. Subjects on MTX should be on an adequate and stable dose of folate supplementation per local standards/regulatory approval (eg, not less than 5 mg weekly based on folic acid, unless such doses would violate the local label guidelines or standard of care) for at least 4 weeks prior to the first dose of investigational product. Subject must not have had previous serious toxicity while on MTX and not be expected to require evaluation for possible methotrexate toxicity (eg, require a liver biopsy for methotrexate toxicity) during the study;
- •Sulfasalazine (Azulfidine®, Salazopyrin®): Maximum dose of 3 gm/day. Minimum duration of therapy 2 months and dose stable for 4 weeks prior to first dose of investigational product.
- •9. Subjects who are already taking oral corticosteroids (not injectables) may participate in the study:
- •Oral corticosteroids: Subjects who are already receiving oral corticosteroids must be on a stable dose of =10 mg/day of prednisone or equivalent for 1 week prior to the first dose of investigational product;
- •Injected (eg, intraarticular, intramuscular, epidural or intravenous) corticosteroids must be discontinued 4 weeks prior to the first dose of investigational product;
- •Topical and intra-rectal cor
排除标准
- •Investigator site staff members directly involved in the conduct of the
- •study and their family members, site staff members otherwise
- •supervised by the investigator, or subjects who are Pfizer employees,
- •including their family members, directly involved in the conduct of the
- •study. Persons who are dependent upon the sponsor, investigator or the
- •study site are excluded.
- •2. Participation in other studies involving investigational drug(s) within
- •4 weeks prior to study entry and/or during study participation
- •(excluding noninterventional follow-up during the screening period).
- •3. Other acute or chronic medical or psychiatric condition including
- •recent (within the past year) or active suicidal ideation or behavior or
- •laboratory abnormality that may increase the risk associated with study
- •participation or investigational product administration or may interfere
- •with the interpretation of study results and, in the judgment of the
- •investigator, would make the subject inappropriate for entry into this
- •4. History of known or suspected complete ankylosis of the spine.
- •5. Subjects that have been exposed to or are currently receiving
- •targeted synthetic DMARDS (including JAK inhibitors), or those currently
- •on biological DMARDs (ie washout from any current bDMARD required
- •per protocol Section 5.8.1), thalidomide (including previous use) and
- •other prohibited concomitant medications.
- •6. History of allergies, intolerance or hypersensitivity to lactose or
- •tofacitinib (CP-690,550). This includes subjects with rare hereditary
- •problems of galactose intolerance, the Lapp lactase deficiency or
- •glucose-galactose malabsorption. The investigators of potential subjects
- •with acquired lactose intolerance should consider whether this is
- •sufficiently concerning so as to preclude participation.
- •7. Blood dyscrasias at screening or within 3 months prior to the first
- •dose of investigational product including confirmed:
- •Hemoglobin <10 g/dL;
- •Absolute white blood cell count (WBC) <3.0 x 10^9/L (<3000 mm3);
- •Absolute neutrophil count (ANC) <1.5 x 10^9/L (<1500 mm3);
- •Absolute lymphocyte count <1.0 x 10^9/L (<1000/mm3);
- •Platelet count <100 x 10^9/L (<100,000/mm3).
- •8. Estimated Creatinine Clearance <40 mL/min based on Cockcroft Gault
- •equation at Screening visit.
- •9. Total bilirubin, AST or ALT more than 1.5 times the upper limit of
- •normal (ULN) at screening visit.
- •One re-testing of a laboratory-acceptable specimen (eg, appropriately
- •labeled, within stability parameters, not hemolyzed, appropriate type
- •(tube and reagent) and volume) is allowed of any above parameters if
- •the abnormal lab(s) was an uncharacteristic result(s). Re-test must be
- •completed within the screening period.
- •10. History of any other autoimmune rheumatic disease.
- •History of an infected joint prosthesis at any time, with the
- •prosthesis still in situ.
- •12. History of any lymphoproliferative disorder, such as Epstein Barr
- •Virus related lymphoproliferative disease (EBV-LPD), history of
- •lymphoma, leukemia, or signs and symptoms suggestive of current
- •lymphatic disease.
- 另有 7 项未显示
研究者
相似试验
进行中（未招募）
不适用
A study in people with Cystic Fibrosis ( a rare hereditary pulmonary disease) to assess the efficacy and safety of a combination of two experimental drugsCystic fibrosis in patients homozygous for the F508del-CFTR MutationMedDRA version: 17.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003989-40-NLVertex Pharmaceuticals Incorporated501
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative ColitisEUCTR2018-003986-33-BEArena Pharmaceuticals, Inc.330
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative ColitisEUCTR2018-003986-33-GBArena Pharmaceuticals, Inc.330
进行中（未招募）
不适用
A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia - LVHJMen with benign prostatic hyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2008-002841-21-ITEli Lilly and Company521
进行中（未招募）
1 期
A study in people with Cystic Fibrosis ( a rare hereditary pulmonary disease) to assess the efficacy and safety of a combination of two experimental drugsCystic fibrosis in patients homozygous for the F508del-CFTR MutationMedDRA version: 16.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003990-24-DKVertex Pharmaceuticals Incorporated501